Pulse Biosciences, Inc · NASDAQ:PLSE
Pulse Biosciences — Investor Presentation (April 2026)
18 slides from Pulse Biosciences's investor presentation, Apr 16, 2026
Slide 1: Corporate Overview
{D) Pulse Biosciences: Corporate Overview April 2026
Slide 2: Forward Looking Statements
Forward Looking Statements {D Pulse Biosciences: {All statements in this presentation that are not historical are forward-looking statements, including, among other things, ‘statements relating to the effectiveness of the Company’s Nanosecond Pulsed Field Ablation (nsPFA) technology and nPulse Syste
Slide 3: Our Mission
Our Mission To build a viable Company that designs, produces, and commercializes nano- pulse technology to improve and extend the lives of patients. To solve the needs of patients, physicians, and healthcare providers with high quality and high reliability products and services, developed in accorda
Slide 4: Experienced Technologists, Operators and Clinicians
Experienced Technologists, Operators and Clinicians From Proven Leadership Team 4 ay wy PaulLaViolette arrin Uecker hie Executive Offic Darrin cook Jon Skinner an of the Board sles hit Financia Off Renowned Scientific Expertise Dr. Gan Dunnington Established Board of Directors Robert (Bob) W. Duggan
Slide 5: Financial & Strategic Snapshot
Financial & Strategic Snapshot - Balance sheet as of 12/31/2025 + Cash and cash equivalents balance of $80.7mm + Nodebt - Cash used in operating activities of $54.1mm in 2025 ~75% + Cash burn increasing: Strategic Capital to support Insider significant clinical opportunities ($14.8mm of cash used Ow
Slide 6: The Nanosecond PFA Advantage - Novel Mechanism, Deeper Ablation
The Nanosecond PFA Advantage - Novel Mechanism, Deeper Ablation mor Thermal 100- | soov L916 ST} 2 J —— + High Thermal Energy + Point to point ablation + Destroys all tissue + Thermal spread risk {D) Pulse Biosciences: nergy-efficient ablation mechanism, enabling larger, deeper, faster, and safer ab
Slide 7: Pioneering nPulse Technology
Pioneering nPulse™ Technology Creating broad and in-depth IP portfolio to effectively own the Nanosecond PFA space PATENT PORTFOLIO 250+ Globally owned or licensed Covering nPulse energy from end-to-end, from generator to electrodes, designed for Generator and System soem § ultra-short high-energy p
Slide 8: EP Market Opportunity +$3.0B
EP Market Opportunity +$3.0B ‘sate AF Ablation Global Atriat Market growingat Crepes) 10-15% Al Drivers for Pulse in the EP AF Ablation Market CAGR' all + Drop-in workflow replacement Front ine clearance and adoption would add significantly ~1.9M' » Speed + efficiency over all prior PFA devices + En
Slide 9: nsPFA Unlocks New Potential in EP
nsPFA Unlocks New Potential in EP | cs) ee 9 LESION + NANOPULSE-AF IDE QUALITY SPEED WORKFLOW EFFICACY approval * Single * Fewer, faster + Map and ablate— Durability, circumferential applications single catheter Goe + Expect to fully enroll IDE eo sTotalPViapeed + Conscious in 2026 neue unmatched ‘s
Slide 10: nsPFA Catheter
nsPFA Catheter Pulmonary Vein Isolation Workflow ner . Ostial a * Two Applications per Pulmonary Vein + Single ostial application + Single antral application yoy + Depending on Anatomy + Single anterior carina applications on each side + Potential additional right-sided lesions on the Pulmonary Vein
Slide 11: nsPFA FIH Trial: Procedure Time and Freedom AF/AFL/AT Success Rate
nsPFA FIH Trial: Procedure Time and Freedom AF/AFL/AT Success Rate sue Comping eat tH 15 » s MPM sions Poser. eos 00735) 7% 2009 camo (trocar Succes ty Hat 5 sano soos 0579 soose2aa “om sowie, 95.7% (45/47) oo 2125 {D) Pulse Biosciences: 0 suo, fcdam hom AF / 0/8 ze Sa g — = ix i H Clinical Roadmap
Slide 12: Strategic Alignment to Accelerate Cardiac Catheter Program
Strategic Alignment to Accelerate Cardiac Catheter Program European feasibility data demonstrates a clear potential to change clinical practice for millions of patients. Updated capital allocation plan assigns highest priority to EP with more concentrated R&D and clinical investment directed to the
Slide 13: NANOPULSE-AF IDE Pivotal Study
NANOPULSE-AF IDE Pivotal Study Target enrollment ~215 patients Clinical sites Up to 30 First patients enrolled 2926 Enrollment target FY 2026 Primary endpoints 6- and 12-months post- ablation procedural success and safety outcomes Status: initial patients treated — 7 in one day from a single, first-
Slide 14: Next Gen nPulse Cardiac Catheter - Development Stage
Next Gen nPulse Cardiac Catheter - Development Stage » Enables Single Catheter Workflow: building on the platform to enable Pulmonary Vein Isolation / Posterior Wall Isolation and Mitral Isthmus / Cavotricuspid Isthmus lines with switchable electrodes + Combines the circumferential rings with a larg
Slide 15: Pulse Biosciences' nPulse Platform
Pulse Biosciences’ nPulse™ Platform . . Opportunity for expansion Multiple High Impact into multiple markets with Opportunities Beyond EP billion dottar plus TAMS — U.S, Addressable Global Status ‘Annual Market Potential Market Cardiac Surgery -Ciictvatation $1.8B $6.0B Enroting Thyroid Application
Slide 16: 2026 Plans
2026 Plans Electrophysiology * Clear safety, speed, workflow, and durability evidence continues to expand * Industry leading efficacy evidence continues to evolve * Complete NANOPULSE AF IDE enrollment * Continued release of clinical data (Heart Rhythm Society 2026) * Progression of Next Generation
Slide 17: Summary
Summary Novel nPulse” Energy * Unique Mechanism of Action * Patent protected + Nonthermal Target Market Values + +$3B US. annual addressable market in EP * Additional opportunities with +$1B markets {D) Pulse Biosciences IP 250+ Owned or Licensed Patents + Pulse effectively owns the Nanosecond PFA S
Slide 18: Citations
Citations 1) Clarivate - US EP Market Report. Data on File. 2) Company filings, BofA Global Research. Revenue is BofA estimate from BofA Global Research Market Report. Data on File. 3) Joglar et alJ.A.C.C. VOL.83,NO.1, 20242023 Guideline for the Diagnosis and Management of Atrial Fibrillation JAN U
Pulse Biosciences — Investor Presentation (April 2026) on 6ix